Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Categorical exclusion under 21 CFR 25.31(c) - RECOTHROM


Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Manufacturing and Product Quality

Date: 06 December 2007

To: BLA STN No. 125248/0

From: Nancy Waites, OCBQ/DMPQBI/ HFM-675

Subject: Categorical exclusion under 21 CFR 25.31(c)

I have reviewed pertinent sections of the Biologics License Application Supplement (STN number 125248/0) from ZymoGenetics, Inc. (ZGI), for the manufacture of Thrombin (recombinant), and find that their request for a categorical exclusion from an environmental assessment under 21 CFR 25.31(c) is justified since the action does not alter significantly the concentration or distribution of the substance, its metabolites, or degradation products in the environment. Thrombin also occurs naturally in the environment.

Nancy Waites Date
Committee Member
Division of Manufacturing Product Quality


John A. Eltermann, Jr., R.Ph.,M.S. Date
Division of Manufacturing Product Quality

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 08/10/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English